Skip to main content
Log in

Renal function and the rate of disappearance of methotrexate from serum

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The disappearance of methotrexate (MTX) from serum was studied using H3-MTX. The overall elimination half-life (MTX T 1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min. The corresponding apparent volume of distribution, V, obtained by extrapolation tended to decrease at lower levels of renal function. The total clearance of MTX calculated in this period varied linearly with creatinine clearance. In patients with normal serum creatinine concentration, the half-life increased with advancing age, which reflects the concurrent age-dependent decrease in creatinine production and renal function. This illustrates the need for knowledge of renal function, not based solely on serum creatinine concentration, in patients treated with methotrexate or other drugs eliminated by the kidneys. In 9 patients the results were not affected by treatment with diuretics (furosemide, hydroflumethiazide). In four patients serum MTX concentration was measured for up to 24–72 hours. An increasing half-life of MTX with time was found, suggesting that the elimination kinetics of the drug would be most adequately described by a multi-compartment model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kunin, M.C.: A guide to use of antibiotics in patients with renal disease. Ann. intern. Med.67 151–158 (1967)

    Google Scholar 

  2. Dettli, L., Spring, P., Ryter, S.: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta pharmacol. (Kbh.)29 211–224 (1967)

    Google Scholar 

  3. Freeman, M.V.: The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (aminopterin) in man. J. Pharmacol. exp. Ther.122 154–162 (1958)

    Google Scholar 

  4. Henderson, E.S., Adamson, R.H., Oliverio, V.T.: The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res.25 1018–1024 (1965)

    Google Scholar 

  5. Huffman, D.H., Wan, S.H., Azarnoff, D.L., Hoogstraten, B.: Pharmacokinetics of methotrexate. Clin. Pharmacol. Ther.14 572–579 (1973)

    Google Scholar 

  6. Farber, S., Diamond, L.K., Mercer, R.D., Sylvester, R.F., Wolff, J.A.: Temporary remissions in acute leukemia in children produced by the folic acid antagonist, 4-amino-pteroylglutamic acid (aminopterin). New Engl. J. Med.238 787–793 (1948)

    Google Scholar 

  7. Li, M.C., Hertz, R., Spencer, D.B.: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc. Soc. exp. Biol. (N.Y.)93 361–366 (1956)

    Google Scholar 

  8. Weinstein, G.D., Frost, P.: Methotrexate for psoriasis. Arch. Derm.103 33–38 (1971)

    Google Scholar 

  9. Rassner, G.: Psoriasis — ihre zytostatische Behandlung mit Amethopterin (Methotrexat). Fortschr. Med.91 381–390 (1973)

    Google Scholar 

  10. Kampmann, J.P., Siersbaek-Nielsen, K., Kristensen, M., Molhølm Hansen, J.: Variations in urinary creatinine and endogenous creatinine clearance due to age. Ugeskr. Laeg.133 2369–2372 (1971)

    Google Scholar 

  11. Siersbaek-Nielsen, K., Molhølm Hansen, J., Kampmann, J., Kristensen, M.: Rapid evaluation of creatinine clearance. Lancet1971 I 1133

    Google Scholar 

  12. Kristensen, M., Molhølm Hansen, J., Skovsted, L.: The influence of phenobarbital on the half-life of diphenylhydantoin in man. Acta med. scand.185 347–350 (1969)

    Google Scholar 

  13. Goldstein, A., Aronow, L., Kalman, S.M.: Principles of drug action. New York, Evanston, London: Harper & Row 1969

    Google Scholar 

  14. Beyer, K.H., Baer, J.E.: Physiological basis for the action of newer diuretic agents. Pharmacol. Rev.13 517–562 (1961)

    Google Scholar 

  15. Liegler, D.G., Henderson, E.S., Hahn, M.A., Oliverio, V.T.: The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther.10 849–857 (1969)

    Google Scholar 

  16. Halprin, K.M., Fului, K., Ohkawara, A.: Blood levels of methotrexate and the treatment of psoriasis. Arch. Derm.103 243–249 (1971)

    Google Scholar 

  17. Dahl, M.C.G., Gregory, M.M., Scheuer, P.J.: Liver damage due to methotrexate in patients with psoriasis. Br. med. J.1971 I 625–630

    Google Scholar 

  18. Weinstein, G., Roenigk, H., Maibach, H., Cosmides, J., Halprin, K., Millard, M.: Psoriasis-liver-methotrexate interactions. Arch. Derm.108 36–42 (1973)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kristensen, L.Ø., Weismann, K. & Hutters, L. Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 8, 439–444 (1975). https://doi.org/10.1007/BF00562319

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562319

Key words

Navigation